BIODESIX, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
BIODESIX, INC. (BDSX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.01 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.01M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.51M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $507.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.01M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-04 |
| 2025-09-30 | $507.00K 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.01M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.51M 10-Q · filed 2025-05-13 |
| 2024-09-30 | $501.00K 10-Q · filed 2024-11-01 |
| 2024-06-30 | $1.01M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.51M 10-Q · filed 2024-05-08 |
| 2023-09-30 | $496.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $990.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.48M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $493.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $986.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.49M 10-Q · filed 2022-05-11 |
| 2021-09-30 | $490.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $976.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $1.46M 10-Q · filed 2021-05-11 |
| 2020-09-30 | $489.00K 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |